PureTech Health: Notice of Half-Yearly Results

Rhea-AI Summary

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has announced plans to release its half-yearly results for the six months ended June 30, 2024, on Wednesday, August 28, 2024. The company will host a presentation and conference call for analysts and shareholders at 9:00am EDT / 2:00pm BST on the same day. Interested parties can access a webcast of the presentation on PureTech's investor relations website. This announcement provides investors and analysts with a scheduled opportunity to review PureTech's financial performance and operational progress for the first half of 2024.

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2024, on Wednesday, August 28, 2024.

A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations.

About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to PureTech’s development plans and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820540519/en/

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com

US Media

Nichole Bobbyn

+1 774 278 8273

nichole@tenbridgecommunications.com

Source: PureTech Health plc

FAQ

When will PureTech Health (PRTC) release its half-yearly results for 2024?

PureTech Health (PRTC) will release its half-yearly results for the six months ended June 30, 2024, on Wednesday, August 28, 2024.

What time is PureTech Health's (PRTC) half-yearly results conference call on August 28, 2024?

PureTech Health's (PRTC) half-yearly results conference call is scheduled for 9:00am EDT / 2:00pm BST on August 28, 2024.

Where can I access the webcast of PureTech Health's (PRTC) half-yearly results presentation?

The webcast of PureTech Health's (PRTC) half-yearly results presentation will be available on the company's investor relations website at https://investors.puretechhealth.com/events-presentations.

What period will PureTech Health's (PRTC) half-yearly results cover?

PureTech Health's (PRTC) half-yearly results will cover the six-month period ended June 30, 2024.